Product Overview
[Drug Name]
Generic Name: Pantoprazole Sodium Enteric-coated Tablets
Trade Name: PanShuTaiKe Pantoprazole Sodium Enteric-coated Tablets 40mg x 7 Tablets
Pinyin Code: PanShuTaiKe ZuoTuoLaZuoNaChangRongPian
[Main Ingredient]
The main ingredient is hemitoprazole sodium. Chemical Name: 5-Difluoromethoxy-2-{[(3,4-dimethoxy-2-pyridyl)methyl]-sulfinyl}-1H-benzimidazole sodium salt monohydrate. Molecular Formula:
C₁₆H₁₄F₂N₃NaO₄S·H₂O Molecular Weight: 423.38
[Properties]
This product is an enteric-coated tablet that appears white after removal of the coating.
[Indications/Main Functions]
It is indicated for active peptic ulcers (gastric and duodenal ulcers), reflux esophagitis, and Zollinger-Ellison syndrome.
[Specifications]
40mg x 7 tablets (Pansutek)
[Dosage and Administration]
For duodenal ulcers, gastric ulcers, and reflux esophagitis, take one tablet orally daily in the morning. The treatment course for duodenal ulcers is typically 2-4 weeks, and for gastric ulcers and reflux esophagitis, it is typically 4-8 weeks.
[Adverse Reactions]
Clinical symptoms may include dizziness, insomnia, drowsiness, nausea, abdominal pain, diarrhea and constipation, abdominal distension, rash, and muscle pain.
[Contraindications]
This product is contraindicated in patients with allergies.
[Drug Interactions]
Not known.
[Precautions]
1. This product is enteric-coated; do not chew it before taking. 2. When gastric ulcers are suspected, the possibility of cancer should be ruled out first, as this product may alleviate symptoms and delay diagnosis. 3. Use with caution in patients with hepatic and renal impairment. In patients with severe liver disease, clearance of this product is delayed, and the dosage should be reduced. 4. This product should not be taken concurrently with other antacids and acid suppressants. To prevent excessive acid suppression, high doses and long-term use are not recommended for conditions such as peptic ulcers, except for Zollinger-Ellison syndrome.
[Pediatric Use]
Efficacy and safety data for pediatric use have not been established.
[Elderly Use]
Unclear.
[Overdose]
Unclear.
[Pharmacology and Toxicology]
This product specifically acts on gastric mucosal parietal cells, reducing the activity of H+-K+-ATPase in these cells, thereby inhibiting gastric acid secretion. Compared with omeprazole, this product has a weaker inhibitory effect on cytochrome P450 enzymes.
